Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2023

  1. Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study

    Lipids, Vol. 58, Núm. 4, pp. 197-206

2020

  1. Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society

    Clinica e Investigacion en Arteriosclerosis, Vol. 32, Núm. 3, pp. 120-125

  2. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes

    Revista Espanola de Cardiologia, Vol. 73, Núm. 9, pp. 718-724

  3. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias

    Clinica e Investigacion en Arteriosclerosis, Vol. 32, Núm. 5, pp. 209-218

2019

  1. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 3, pp. 128-139

  2. Non-HDL cholesterol as a therapeutic goal

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 28-33

  3. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

    Clinica e Investigacion en Arteriosclerosis

  4. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2018

  1. COSMIC project: Consensus on the objectives of the metabolic syndrome in clinic

    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 11, pp. 683-697

  2. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

    Clinica e Investigacion en Arteriosclerosis, Vol. 30, Núm. 4, pp. 188-192

2017

  1. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study

    American Journal of Cardiovascular Drugs, Vol. 17, Núm. 2, pp. 135-142

  2. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia

    Scientific Reports, Vol. 7, Núm. 1

  3. Enfermedad renal crónica y dislipidemia

    Clinica e Investigacion en Arteriosclerosis

  4. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease

    Clinica e Investigacion en Arteriosclerosis

  5. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease

    Clinica e Investigacion en Arteriosclerosis

  6. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients

    American Journal of Cardiology, Vol. 119, Núm. 5, pp. 742-748

2016

  1. Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: Estudio Diana

    Clinica e Investigacion en Arteriosclerosis, Vol. 28, Núm. 3, pp. 132-140

  2. Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study

    Nefrologia, Vol. 36, Núm. 6, pp. 679-686

  3. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship

    Circulation: Cardiovascular Genetics, Vol. 9, Núm. 6, pp. 504-510

2015

  1. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients

    Atherosclerosis, Vol. 238, Núm. 2, pp. 213-219